Rakoczy Molino Mazzochi Siwik is a Chicago-based IP boutique exclusively dedicated to handling life sciences clients. The practice has more than 40 attorneys, a majority of whom hold advanced scientific degrees in a variety of subjects, including chemistry, biochemistry, molecular biology, biomedical engineering and pharmacy. Rakoczy Molino is particularly strong in the area of Hatch-Waxman litigation, representing generic companies in the small molecule space, and is also equipped to handle litigations in the burgeoning practice area under the Biologics Price Competition and Innovation Act. Since the firm was founded in 2004, its practitioners handled more than 240 Hatch-Waxman litigations and related matters.
Founding partners William Rakoczy and Paul Molino head substantial IP litigation practices, sharing extensive first-chair experience between the two of them. Rakoczy has handled matters at both the trial and appellate level, including cases related to blockbuster drugs such as Truvada, Lipitor, Prozac and Zoloft. Molino is also heavily involved in Hatch-Waxman work, seeing cases through from the pre-litigation phase up to trial. His past representations include cases related to high-selling drugs Cymbalta, Nasonex, Neurontin and Crestor.
